US 9,427,401 B2Granted

Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes

AssigneeAllergan, Inc.

InventorsWha-Bin Im, Robert M. Burk

Life of this patent

Estimating the term…

Abstract

Compositions and methods for treating glaucoma are provided. In particular hydrophilic ester prodrugs and their use to reduce central corneal thickening is provided.

Claims6

Dependent claims

A compound having Formula (III):

wherein:
n is 3 to 5;
and
R2D at each occurrence is independently hydrogen or hydroxyl, and wherein 1, 2, 3, 4, or 5 R2D substituents are not hydrogen.

1 more element

Dependencies are inferred from the claim text.

Facts

Application: 14/685,414Filed 13 Apr 2015 · continuation
Priority: 27 Aug 2012
Published: US 2015/0322036 A112 Nov 2015
Granted: 30 Aug 2016
Term ends: Not estimatedThe source records don’t support an estimate.

Classification9 codes

A61K 9/0048
Galenical forms characterised by the site of application: eye, e.g. artificial tears
A61K 31/381
Having sulfur as a ring hetero atom: having five-membered rings
A61P 27/06
Ophthalmic agents: antiglaucoma agents or miotics
C07D 333/38
With hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals,…:…

Family

Application61/693,437Us provisional application · filed 27 Aug 2012
Application13/974,975Parent of this continuation · filed 23 Aug 2013
US 2015/0322036 A1Pre-grant publication · published 12 Nov 2015
US 9,024,042 B2Parent of this continuation
US 2014/0057975 A1Published application
US 9,427,401 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results